The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $419.36

Today's change-2.09 -0.50%
Updated September 28 3:37 PM EDT. Delayed by at least 15 minutes.
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $419.36

Today's change-2.09 -0.50%
Updated September 28 3:37 PM EDT. Delayed by at least 15 minutes.

Reversal following new 20-day high

Regeneron Pharmaceuticals Inc is lower today, dropping (U.S.)$2.09 or 0.50% to (U.S.)$419.36 after setting a new 20-day high. Over the last five days, shares have gained 3.16%, but are down 22.75% for the last year to date. Shares have underperformed the S&P 500 by 22.79% during the last year.

Key company metrics

  • Open(U.S.) $421.88
  • Previous close(U.S.) $421.45
  • High(U.S.) $424.35
  • Low(U.S.) $418.38
  • Bid / Ask(U.S.) $418.92 / (U.S.) $419.34
  • YTD % change-22.75%
  • Volume689,022
  • Average volume (10-day)767,461
  • Average volume (1-month)715,224
  • Average volume (3-month)814,322
  • 52-week range(U.S.) $329.09 to (U.S.) $592.59
  • Beta1.31
  • Trailing P/E65.46×
  • P/E 1 year forward38.32×
  • Forward PEG2.06×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $6.41
Updated September 28 3:37 PM EDT. Delayed by at least 15 minutes.
S&P TSX1.12%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015
Revenue1,2131,2011,0981,137
Total other revenue--------
Total revenue1,2131,2011,0981,137
Gross profit1,1441,0899871,028
Total cost of revenue69112111109
Total operating expense921872869745
Selling / general / administrative292290295210
Research & development560470461426
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)----20
Other operating expenses, total--------
Operating income292329229392
Interest income (expense), net non-operating-----4-2
Gain (loss) on sale of assets--------
Other--------
Income before tax292330227393
Income after tax196181155210
Income tax, total9614972183
Net income196181155210
Total adjustments to net income--------
Net income before extra. items196181155210
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items196181155210
Inc. avail. to common incl. extra. items196181155210
Diluted net income196182155210
Dilution adjustment000--
Diluted weighted average shares116116115116
Diluted EPS excluding extraordinary itemsvalue per share1.691.561.341.81
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share1.691.561.351.81